SB Research
reacted to
$Surf Air Mobility (SRFM.US)$ $Palantir (PLTR.US)$
Why Would Palantir Keep Buying SurfAir Mobility shares? Potential M&A? Very Speculative!
When the market was skeptical, I recommended buying this stock after the secondary offering. Now, I’m advising that institutional investors may start accumulating shares once it breaks the $10 mark, potentially driving the price higher. If you invested below $5, congratulations! However, it’s time to consider an exit strategy...
Why Would Palantir Keep Buying SurfAir Mobility shares? Potential M&A? Very Speculative!
When the market was skeptical, I recommended buying this stock after the secondary offering. Now, I’m advising that institutional investors may start accumulating shares once it breaks the $10 mark, potentially driving the price higher. If you invested below $5, congratulations! However, it’s time to consider an exit strategy...



+1
5
2
$Applovin (APP.US)$ $Robinhood (HOOD.US)$ One of these missed their chance to enter.
Datadog Shares Are Trading Higher After It Was Announced That the Company Will Join the S&P 500, Effective Before the Opening of Trading on July 9, 2025.
$Datadog (DDOG.US)$ swaps $Juniper Networks(Delisted) (JNPR.US)$ in the S&P 500
With the Juniper Networks being part of $Hewlett Packard Enterprise (HPE.US)$ , in my opinion the one company that will benefit big time from thi...
Datadog Shares Are Trading Higher After It Was Announced That the Company Will Join the S&P 500, Effective Before the Opening of Trading on July 9, 2025.
$Datadog (DDOG.US)$ swaps $Juniper Networks(Delisted) (JNPR.US)$ in the S&P 500
With the Juniper Networks being part of $Hewlett Packard Enterprise (HPE.US)$ , in my opinion the one company that will benefit big time from thi...



+1
2
SB Research
reacted to
$Super Micro Computer (SMCI.US)$
Click to read my orginal post —> What if
Many were saying short short short SMCI, and it was rare to see a bull out there. There was 🩸 in the streets and thats were I took my chance (risk) to buy SMCI and wrote What If.
I believe now the stock will meet requirements to remain listed in the Nasdaq. I also believe that many analysts will raise there rating on the stock too and price target. Im not saying Super Micro is perfect but its still a huge ...
Click to read my orginal post —> What if
Many were saying short short short SMCI, and it was rare to see a bull out there. There was 🩸 in the streets and thats were I took my chance (risk) to buy SMCI and wrote What If.
I believe now the stock will meet requirements to remain listed in the Nasdaq. I also believe that many analysts will raise there rating on the stock too and price target. Im not saying Super Micro is perfect but its still a huge ...
5
SB Research
reacted to
$Surf Air Mobility (SRFM.US)$
partners since 2021
Breaking News
With the lastest announcement ^^, personally I feel like its a good entry point to BUY a very speculative stock like SRFM. Palatir now has stake of 20% of SRFM shares and could be for multiple reasons, but lets keep it simple of why they kept on buying shares of Surf Air Mobility.
$Palantir (PLTR.US)$ likely purchased Surf Air Mobility (SRFM) share...
partners since 2021
Breaking News
With the lastest announcement ^^, personally I feel like its a good entry point to BUY a very speculative stock like SRFM. Palatir now has stake of 20% of SRFM shares and could be for multiple reasons, but lets keep it simple of why they kept on buying shares of Surf Air Mobility.
$Palantir (PLTR.US)$ likely purchased Surf Air Mobility (SRFM) share...



+2
4
1
2
SB Research
reacted to
$NEBIUS (NBIS.US)$ vs $DigitalOcean (DOCN.US)$ a stock under WallStreet radar.
please read-> DOCN - AI Compute Power Efficiency Winner - Updated vs NBIS
thank you for your time.
$CoreWeave (CRWV.US)$ $Applied Digital (APLD.US)$ $NVIDIA (NVDA.US)$
.
please read-> DOCN - AI Compute Power Efficiency Winner - Updated vs NBIS
thank you for your time.
$CoreWeave (CRWV.US)$ $Applied Digital (APLD.US)$ $NVIDIA (NVDA.US)$
.
8
SB Research
liked
$DigitalOcean (DOCN.US)$
DigitalOcean supports AI workloads with its compute services, including virtual machines (Droplets), Kubernetes, and serverless Functions. Its infrastructure offers scalability, flexibility, and cost-effectiveness, making it suitable for AI tasks like model training, deployment, and data processing. DigitalOcean's services enable users to deploy machine learning frameworks, utilize GPU acceleration, and store larg...
DigitalOcean supports AI workloads with its compute services, including virtual machines (Droplets), Kubernetes, and serverless Functions. Its infrastructure offers scalability, flexibility, and cost-effectiveness, making it suitable for AI tasks like model training, deployment, and data processing. DigitalOcean's services enable users to deploy machine learning frameworks, utilize GPU acceleration, and store larg...



+2
2
3
$Navitas Semiconductor (NVTS.US)$
Navaitas was a choppy stock to own last year, but the great partnerships and the new datacenters win with $NVIDIA (NVDA.US)$ this year may look brighter for shareholders. Navitas has great technology suites and pipelines ahead of them, and expect other companies like $Advanced Micro Devices (AMD.US)$ to use GaN technology. As I stated before back in Sep 20, 2024.
Buying Opportunity? Execution is Key 🔑
In my opinion Navitas has moment...
Navaitas was a choppy stock to own last year, but the great partnerships and the new datacenters win with $NVIDIA (NVDA.US)$ this year may look brighter for shareholders. Navitas has great technology suites and pipelines ahead of them, and expect other companies like $Advanced Micro Devices (AMD.US)$ to use GaN technology. As I stated before back in Sep 20, 2024.
Buying Opportunity? Execution is Key 🔑
In my opinion Navitas has moment...

4
2
$Merus (MRUS.US)$
Merus (MRUS) N.V. “announced interim clinical data as of a February 27, 2025 data cutoff from the ongoing phase 2 trial of the bispecific antibody petosemtamab in combination with pembrolizumab. These data will be presented by Dr. Carla M. L. van Herpen M.D. Ph.D., Radboud University Medical Center, Nijmegen, Netherlands at the 2025 American Society of Clinical Oncology(R) Annual Meeting on Monday, June 2 at 9 a.m. – 12:00 p.m. CT.” “By essentially...
Merus (MRUS) N.V. “announced interim clinical data as of a February 27, 2025 data cutoff from the ongoing phase 2 trial of the bispecific antibody petosemtamab in combination with pembrolizumab. These data will be presented by Dr. Carla M. L. van Herpen M.D. Ph.D., Radboud University Medical Center, Nijmegen, Netherlands at the 2025 American Society of Clinical Oncology(R) Annual Meeting on Monday, June 2 at 9 a.m. – 12:00 p.m. CT.” “By essentially...



1